305 related articles for article (PubMed ID: 20586715)
1. Non-ATP competitive protein kinase inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2010; 17(25):2804-21. PubMed ID: 20586715
[TBL] [Abstract][Full Text] [Related]
2. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
Zhang Q; Zhang X; You Q
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
[TBL] [Abstract][Full Text] [Related]
3. Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases.
Zhu Y; Hu X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296718
[TBL] [Abstract][Full Text] [Related]
4. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
5. Type II Inhibitors Targeting CDK2.
Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
[TBL] [Abstract][Full Text] [Related]
6. Irreversible protein kinase inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2011; 18(20):2981-94. PubMed ID: 21651479
[TBL] [Abstract][Full Text] [Related]
7. Recent development of cyclic amide (pyridone/lactam) moiety containing heterocycles as protein kinase inhibitors.
Wei L; Malhotra SV
Curr Med Chem; 2010; 17(3):234-53. PubMed ID: 20214566
[TBL] [Abstract][Full Text] [Related]
8. Aromatic Rings as Molecular Determinants for the Molecular Recognition of Protein Kinase Inhibitors.
Zhu Y; Alqahtani S; Hu X
Molecules; 2021 Mar; 26(6):. PubMed ID: 33810025
[TBL] [Abstract][Full Text] [Related]
9. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes.
Roskoski R
Pharmacol Res; 2016 Jan; 103():26-48. PubMed ID: 26529477
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinases inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2012; 19(23):3937-48. PubMed ID: 22709006
[TBL] [Abstract][Full Text] [Related]
11. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
12. Substituent Effects on Drug-Receptor H-bond Interactions: Correlations Useful for the Design of Kinase Inhibitors.
Lawhorn BG; Philp J; Graves AP; Holt DA; Gatto GJ; Kallander LS
J Med Chem; 2016 Dec; 59(23):10629-10641. PubMed ID: 27933961
[TBL] [Abstract][Full Text] [Related]
13. Small molecule kinase inhibitors as anti-cancer therapeutics.
Chahrour O; Cairns D; Omran Z
Mini Rev Med Chem; 2012 May; 12(5):399-411. PubMed ID: 22303944
[TBL] [Abstract][Full Text] [Related]
14. Rational design of inhibitors that bind to inactive kinase conformations.
Liu Y; Gray NS
Nat Chem Biol; 2006 Jul; 2(7):358-64. PubMed ID: 16783341
[TBL] [Abstract][Full Text] [Related]
15. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.
Ung PM; Schlessinger A
ACS Chem Biol; 2015 Jan; 10(1):269-78. PubMed ID: 25420233
[TBL] [Abstract][Full Text] [Related]
16. Evolutionary variation and adaptation in a conserved protein kinase allosteric network: implications for inhibitor design.
Oruganty K; Kannan N
Biochim Biophys Acta; 2013 Jul; 1834(7):1322-9. PubMed ID: 23499783
[TBL] [Abstract][Full Text] [Related]
17. TAK1 selective inhibition: state of the art and future opportunities.
Kilty I; Jones LH
Future Med Chem; 2015; 7(1):23-33. PubMed ID: 25582331
[TBL] [Abstract][Full Text] [Related]
18. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.
Rettenmaier TJ; Sadowsky JD; Thomsen ND; Chen SC; Doak AK; Arkin MR; Wells JA
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18590-5. PubMed ID: 25518860
[TBL] [Abstract][Full Text] [Related]
19. ATP non-competitive Ser/Thr kinase inhibitors as potential anticancer agents.
Cozza G; Bortolato A; Menta E; Cavalletti E; Spinelli S; Moro S
Anticancer Agents Med Chem; 2009 Sep; 9(7):778-86. PubMed ID: 19799530
[TBL] [Abstract][Full Text] [Related]
20. From Type I to Type II: Design, Synthesis, and Characterization of Potent Pyrazin-2-ones as DFG-Out Inhibitors of PDGFRβ.
Bethke E; Pinchuk B; Renn C; Witt L; Schlosser J; Peifer C
ChemMedChem; 2016 Dec; 11(24):2664-2674. PubMed ID: 27885822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
